Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

86
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
86
Elements Crucial for Effective Psychotherapy01:25

Elements Crucial for Effective Psychotherapy

43
Research has highlighted several critical factors that influence the effectiveness of psychotherapy, such as the therapeutic alliance, the therapist, and the client.
The Therapeutic Alliance
The therapeutic alliance refers to the relationship between the therapist and the client. The alliance strengthens when the therapist and the client engage in a nurturing, supportive, trusting, empathetic, and respectful relationship, improving therapeutic outcomes. Therapists must monitor this relationship...
43
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
T Cell Types and Functions01:24

T Cell Types and Functions

1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prevalence And Factors Associated With Patient-clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced Therapy

Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced Therapy

Jeffrey R Curtis1, Robert R McLean2, I-Heng Lee3

  • 1University of Alabama at Birmingham.

ACR Open Rheumatology
|March 2, 2024

Related Experiment Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

134
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

383
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

97

View abstract on PubMed

Summary
This summary is machine-generated.

Patient and clinician assessments of rheumatoid arthritis (RA) disease activity often differ, especially when starting new biologic or Janus kinase inhibitor (JAKi) therapies. Identifying factors associated with this discordance can improve patient-centered care.

Area of Science:

  • Rheumatology
  • Clinical Trial Analysis
  • Patient-Reported Outcomes

Background:

  • Patient-clinician discordance in disease assessment is a recognized challenge in managing rheumatoid arthritis (RA).
  • Understanding factors influencing this discordance is crucial for optimizing treatment strategies, particularly at the initiation of advanced therapies like biologics or Janus kinase inhibitors (JAKi).

Purpose of the Study:

  • To describe the prevalence of patient-clinician discordance in disease assessment among rheumatoid arthritis (RA) patients initiating their first biologic or JAKi.
  • To identify factors associated with this discordance at therapy initiation and over 12 months of follow-up in a real-world US registry.

Main Methods:

  • Analysis of data from the CorEvitas RA Registry, including patients initiating their first biologic or JAKi from February 1, 2015, onwards.

Related Experiment Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

134
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

383
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

97
  • Definition of positive discordance as a ≥30-point difference between patient and physician global assessments (VAS-100).
  • Use of mixed-effects logistic regression to identify risk factors for positive and persistent discordance at initiation and follow-up visits.

    • Main Results:

    • Approximately 30% of patients exhibited positive discordance at any visit, with 10% showing persistent discordance across three visits.
    • Factors associated with discordance at initiation included worse Clinical Disease Activity Index scores, increased patient-reported pain, fatigue, and functional impairment.
    • Persistent discordance was linked to disability status, female sex (higher odds), and Medicare insurance (lower odds).

    Conclusions:

    • Patient-clinician discordance in disease assessment is common in rheumatoid arthritis (RA) patients starting biologic or JAKi therapy.
    • Identified risk factors highlight the need for patient-centric discussions to align treatment decisions with patient experiences and improve therapeutic outcomes.